TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02302937

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )
Description: laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B will undergo laparoscopic TEP inguinal hernia repair with a single port
Description: Group B will undergo laparoscopic TEP inguinal hernia repair with a single port LESS (12 to 15 mm transumbilical).
Study: NCT04093154

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing the virtual headset
Description: watching the application by wearing virtual glasses to the child/adolescent
Study: NCT01487434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check & Connect
Description: Structured mentoring and case management
Study: NCT04002739

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polygraphy
Description: Patients will perform polygraphy during the CCU stay (baseline) and, if found to have a diagnosis of Obstructive Sleep Apnea (OSA) syndrome, will complete the study with a follow-up visit at 90-day (follow-up). Diagnosis of OSA syndrome will require an Apnea / Hypopnea Index (AHI) more than 5 events per hour.
Study: NCT00260273

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behaviour Therapy
Description: therapy
Study: NCT01461291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent inject
Description: Implantation of two GTS400 stents using G2-M-IS iStent inject

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract surgery alone
Study: NCT01192399

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eculizumab
Study: NCT03408431

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu® AuraGain™
Description: Ambu® AuraGain™ laryngeal mask will be placed first, and then, a lubricated endotracheal tube will be gently intubated through the laryngeal mask under each position according to the assigned group.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu® AuraGain™
Description: Ambu® AuraGain™ laryngeal mask will be placed first, and then, a lubricated endotracheal tube will be gently intubated through the laryngeal mask under each position according to the assigned group.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neck extension
Description: Patients' neck will be maximally extended (\~60°) during blind intubation.
Study: NCT02997722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV infusion of ketamine 0.5 mg/kg administered over 45 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: IV infusion of 100 ml of normal saline over 45 minutes.
Study: NCT03822273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (TA)
Description: Procedure: real acupuncture.~Eight disposable, single use, sterilized, stainless steel needles are inserted at each session, and the bilateral LI4 (Hegu), SJ6 (Zhigou), ST36 (Zusanli) and GB34 (Yanglingquan) are used for acupuncture treatment. The acupuncture needles are to be inserted to a depth of 15-35 mm. All needles are rotated manually at least once at each session to elicit needle sensation (De qi). The needle retention time is 15 min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser acupuncture (LA)
Description: Procedure: laser acupuncture.~Participants allocated to the LA group receive laser acupuncture treatment at the same acupoints used in acupuncture group. The laser acupuncture therapy will be performed with the gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5 Hz, B2: 1199 Hz, B3: 2398 Hz, B4: 4776 Hz, B5: 9552 Hz, B6: 19,104 Hz, and B7: 38,208 Hz\]; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser will be applied to each point for 5 seconds, which delivered 0.375 J of energy at each of the acupoints: LI4 (Hegu, B3), SJ6 (Zhigou, B3), ST36 (Zusanli, B2) and GB34 (Yanglingquan, B2).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham laser acupuncture (SLA)
Description: Procedure: sham laser acupuncture.~Subjects in the control group receive sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in the LA group.
Study: NCT02991352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Image guided needle placement
Description: Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
Study: NCT02785627

Intervention type: OTHER
Intervention: Comprehensive bone health assessment
Description: Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius

Intervention type: OTHER
Intervention: Comprehensive bone health assessment
Description: Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius

Intervention type: OTHER
Intervention: Comprehensive bone health assessment
Description: Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius
Study: NCT01011556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Teriparatide
Description: Administered subcutaneously once daily for 12 months
Study: NCT02040909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol, an anesthetic agent, is used to sedate the patients before endotracheal intubation. The propofol starting dose in all age groups will be 1.0 mg propofol/kg. After 5 patients per age group the next dose will be determined. Dose will be increased or decreased with 0.5 mg/kg for the next 5 patients. The study will be continued untill an adequate dose, that results in adequate sedation, good intubation conditions without hypotension, is determined. That dose will be valideted in another 5 patients per age group.
Study: NCT02644070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alveolar bone preservation with mp3
Description: graft with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alveolar bone preservation with apatos
Description: graft with cortical porcine bone (Apatos, Osteobiol, Coazze, Italy )

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stabilization with membrane
Description: socket stabilization with a collagen membrane (Evolution, Osteobiol, Coazze, Italy)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stabilization with membrane
Description: socket stabilization with a collagen membrane (Evolution, Osteobiol, Coazze, Italy)
Study: NCT02959346

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Procedure:~Sham Acupuncture(ipisilateral side, 0.3cun, No needle sensation (de qi) was elicited) Sham acupuncture will be applied by inserting acupuncture needle into acupoints(1cm away from the true acupoint):upper limb: Waiguan TE5; lower limb: Zusanli ST36.~All procedures were carried out to a depth of 0.5 cm with disposable needles measuring 0.16 mm in diameter (40-gauge) and 12.7 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Procedure:~Acupuncture(ipisilateral side, the needling depth decided by whether patients feel De qi, neutral supplementation and draining) Acupuncture will be applied by inserting acupuncture needle into acupoints: Zhigou TE6, Shousanli LI10, Hegu LI4, Neiguan PC6, Houxi SI3; lower limb: Biguan ST31, Fushe SP13, Zulinqi GB41; axillary area(Remove Needles right away after De qi): Yuanye GB22, Jiquan HT1; local area(Remove Needles right away after De qi): ashi point close to the pain area.~The other needles will be left for 20 minutes and then removed. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery.
Study: NCT00811850

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
Description: 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
Description: 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
Study: NCT03988205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient Care Model
Description: Outpatient care model includes a nurse teacher educational program, scheduled outpatient visit protocol, and quality of life surveys for both subjects and caregivers.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is administered, according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
Study: NCT03085953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veteran Supportive Supervisor Training
Description: The family supportive supervisor behavior (FSSB) training intervention developed by Hammer and colleagues (2011) will be used as the basis for the development of the VSST intervention in the present study. In addition, we will draw on critical elements of training provided by the Employer Support of the Guard and Reserve (ESGR), information about potential mental and physical health effects of being in combat, and information to help reduce the stigma associated with returning veterans; in other words, de-clinicalizing their symptoms. Furthermore, this intervention study falls under the more general rubric of soldier resilience, but more specifically addresses both veteran and family resilience upon return from combat. The details of the training content will be researched and developed during the funded project period.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: Control group will receive training following all measurements points to serve as a comparison group
Study: NCT03246412

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nevus doctor clinical decision support
Description: The computer program analyzes dermatoscopic images. The output is an estimate of the risk of the skin lesion representing skin cancer. The decision support tool helps the doctor to assess the significance of the computer output by taking into account clinical information.
Study: NCT00879398

Intervention type: DRUG
Intervention: Toviaz treatment
Description: 4 mg starting then can be followed by 8 mg
Study: NCT02082379

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: inhaled normal saline using different interfaces.
Description: A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: inhaled normal saline using different interfaces.
Description: A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.
Study: NCT01799135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DCE-MRI scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Study: NCT01770496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Childhood vaccination reminder / recall notification
Study: NCT04289623

Intervention type: BEHAVIORAL
Intervention: Email
Description: Email

Intervention type: BEHAVIORAL
Intervention: Email
Description: Email

Intervention type: BEHAVIORAL
Intervention: Email
Description: Email

Intervention type: BEHAVIORAL
Intervention: Email
Description: Email

Intervention type: BEHAVIORAL
Intervention: Email
Description: Email

Intervention type: BEHAVIORAL
Intervention: Email
Description: Email

Intervention type: BEHAVIORAL
Intervention: Loss frame
Description: Email

Intervention type: BEHAVIORAL
Intervention: Testimonial (medical expert)
Description: Email

Intervention type: BEHAVIORAL
Intervention: Testimonial (rank-and-file)
Description: Email

Intervention type: BEHAVIORAL
Intervention: Social norms (percentage)
Description: Email

Intervention type: BEHAVIORAL
Intervention: Social norms (number)
Description: Email
Study: NCT04185948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet guidelines plus intermittent fasting
Description: For 4 weeks participants will be encouraged to adopt the Mediterranean dietary guidelines as recommended by the Mediterranean Diet Foundation in Barcelona, Spain. In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UK Eatwell guidelines plus intermittent fasting
Description: For 4 weeks participants will be encouraged to adopt the UK dietary guidelines (Eatwell Guide). In combination with these guidelines, an intermittent fasting regime involving two days of the week will be implemented. The regime will encourage individuals to consume of 500kcal per day for women and 625kcal per day for men, resulting in 75% daily caloric restriction during each of these two days.
Study: NCT02700113

Intervention type: OTHER
Intervention: No intervention
Description: Intervention is not a part of this study. This is a behavioral phenotyping study of minimally verbal individuals with Autism Spectrum Disorder.
Study: NCT03758443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 Dose A
Description: See Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 Dose B
Description: See Arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1473 Dose C
Description: See Arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Arm description
Study: NCT01951222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V0162

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01224964

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast, 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: long acting beta2 mimetic
Description: ICS+long acting beta2 agonist: twice daily
Study: NCT00199875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)
Description: Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)
Description: Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)
Description: Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)
Description: Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-90 conjugated chimeric G250 (^90Y-DOTA-cG250)
Description: Patients received a single infusion of \^90Y-DOTA-cG250, with escalating doses administered to sequentially enrolled cohorts until MTD determination.
Study: NCT00887874

Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire when entering the observational study.
Study: NCT00408460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study: NCT03617185

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training (HIIT)
Description: Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity Interval Training (HIIT)
Description: Patients will complete a HIIT training protocol of a total of 10 x 1 min intervals at 90% heart rate (HR) max. They will continue this training protocol, 3 sessions a week (2 supervised and 1 unsupervised), for 24 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Exercise
Description: Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).
Study: NCT04356755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AdMSC
Description: At day 0, patients will have AdMSC injections in their ischemic DU. Patients will be followed-up for 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At day 0, patients will have placebo injections in their ischemic DU. Patients will be followed-up for 16 weeks
Study: NCT03400696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate diet
Description: Focused on limiting dietary carbohydrates, eating healthy fat and protein sources, and engaging in physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lower carbohydrate diet
Description: Focused on limiting dietary carbohydrates, eating healthy fat and protein sources, and engaging in physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher fiber diet
Description: Focused on increasing dietary fiber, lowering fat intake from animal sources, and engaging in physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Higher fiber diet
Description: Focused on increasing dietary fiber, lowering fat intake from animal sources, and engaging in physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity focused
Description: Focused on aerobic and resistance exercise, while following dietary guidelines \<https://www.choosemyplate.gov\>

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity focused
Description: Focused on aerobic and resistance exercise, while following dietary guidelines \<https://www.choosemyplate.gov\>
Study: NCT03009331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lungrecruitment manoeuver in prone position.
Description: Postoperative lungrecruitment in prone position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lungrecruitment manoeuver in supine position.
Description: Postoperative lungrecruitment in supine position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
Study: NCT02196142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisol 20mg
Description: Drug: Cortisol 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisol 20mg
Description: Drug: Cortisol 20mg
Study: NCT01011556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Teriparatide
Description: Administered transdermally, applied once daily for 6 hours over 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Teriparatide
Description: Administered transdermally, applied once daily for 6 hours over 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Teriparatide
Description: Administered transdermally, applied once daily for 6 hours over 12 months
Study: NCT02396290

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide laser with platelet rich plasma
Description: fractional carbon dioxide laser followed by platelet rich plasma injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fractional carbon dioxide laser with NS
Description: fractional carbon dioxide laser followed by normal saline injection
Study: NCT03617185

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Exercise
Description: Patients will receive counseling regarding exercise as a routine part of their participation in the bariatric surgery clinic. Specifically, they are counseled to participate in 60 min of aerobic exercise daily in addition to 2-3 non-consecutive days of strength training workouts every wk. Patients are encouraged to contact the bariatric conditioning program, obtain a gym membership, purchase exercise equipment, join a walking group, and/or sign up for fitness classes (employer or city parks and recreation).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Patients will undergo bariatric surgery as part of their routine care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Description: Patients will undergo bariatric surgery as part of their routine care